trial
as of 2026-07-01Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)
NCTId NCT04624243
at a glance
Phase 2 · Completed
Enrollment 499 (actual)
Sponsored by Merck Sharp & Dohme LLC
Primary completion 2024-06-21
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
499 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2020-12-15
Primary completion
2024-06-21
Eligibility
ALL · 18 Years · 55 Years
Interventions & indications
Indications
Sponsors
Merck Sharp & Dohme LLCLead Sponsor
Sites
121 total
Bentonville, United StatesLittle Rock, United StatesRogers, United StatesBellflower, United StatesCulver City, United StatesGarden Grove, United StatesGlendale, United StatesRiverside, United StatesSan Diego, United StatesSan Diego, United StatesSherman Oaks, United StatesHollywood, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
499
Phase
PHASE2
Primary Completion Date
2024-06-21
Status
COMPLETED
relationships
The graph out of here
drug
drug
drug
lead_sponsor
company
indication
indication
indication